PE20190445A1 - Moduladores del receptor beta-3 adrenergico de utilidad para el tratamiento o la prevencion de trastornos relacionados con ellos - Google Patents
Moduladores del receptor beta-3 adrenergico de utilidad para el tratamiento o la prevencion de trastornos relacionados con ellosInfo
- Publication number
- PE20190445A1 PE20190445A1 PE2018003180A PE2018003180A PE20190445A1 PE 20190445 A1 PE20190445 A1 PE 20190445A1 PE 2018003180 A PE2018003180 A PE 2018003180A PE 2018003180 A PE2018003180 A PE 2018003180A PE 20190445 A1 PE20190445 A1 PE 20190445A1
- Authority
- PE
- Peru
- Prior art keywords
- heart failure
- heart
- failure
- left ventricular
- beta
- Prior art date
Links
- 102000016959 beta-3 Adrenergic Receptors Human genes 0.000 title abstract 3
- 108010014502 beta-3 Adrenergic Receptors Proteins 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title 1
- 206010019280 Heart failures Diseases 0.000 abstract 11
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 abstract 3
- 206010007556 Cardiac failure acute Diseases 0.000 abstract 2
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 2
- 206010024119 Left ventricular failure Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 206010067125 Liver injury Diseases 0.000 abstract 1
- 238000002583 angiography Methods 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000002592 echocardiography Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000003709 heart valve Anatomy 0.000 abstract 1
- 231100000234 hepatic damage Toxicity 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 230000008818 liver damage Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 230000008816 organ damage Effects 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 230000033764 rhythmic process Effects 0.000 abstract 1
- 230000002861 ventricular Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La presente invencion se refiere a compuestos de la formula (la) y sus composiciones farmaceuticas que modulan la actividad del receptor beta-3 adrenergico. Los compuestos de la presente invencion y sus composiciones farmaceuticas se dirigen a metodos de utilidad en el tratamiento de un trastorno mediado por el receptor beta-3 adrenergico tales como insuficiencia cardiaca; rendimiento cardiaco en insuficiencia cardiaca; mortalidad, reinfarto, y/u hospitalizacion en relacion con insuficiencia cardiaca; insuficiencia cardiaca aguda; insuficiencia cardiaca descompensada aguda; insuficiencia cardiaca congestiva; insuficiencia cardiaca congestiva severa; dano en los organos asociado con insuficiencia cardiaca (por ejemplo, dano o insuficiencia renal, problemas de las valvulas cardiacas, problemas del ritmo cardiaco, y/o dano hepatico); insuficiencia cardiaca debida a disfuncion ventricular izquierda; insuficiencia cardiaca con fraccion de eyeccion normal; mortalidad cardiovascular despues de un infarto de miocardio; mortalidad cardiovascular en pacientes con insuficiencia ventricular izquierda o disfuncion ventricular izquierda; insuficiencia ventricular izquierda; disfuncion ventricular izquierda; insuficiencia cardiaca de clase II en base al sistema de clasificacion de la New York Heart Association (NYHA); insuficiencia cardiaca de clase 111 en base al sistema de clasificacion de la New York Heart Association (NYHA); insuficiencia cardiaca de clase IV en base al sistema de clasificacion de la New York Heart Association (NYHA); LVEF < 40% por ventriculografia de radionuclidos; LVEF <=35 % por ecocardiografia o angiografia ventricular de contraste; y condiciones patologicas relacionadas con ello.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662346293P | 2016-06-06 | 2016-06-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20190445A1 true PE20190445A1 (es) | 2019-03-29 |
Family
ID=59067920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018003180A PE20190445A1 (es) | 2016-06-06 | 2017-06-05 | Moduladores del receptor beta-3 adrenergico de utilidad para el tratamiento o la prevencion de trastornos relacionados con ellos |
Country Status (29)
| Country | Link |
|---|---|
| US (5) | US20190284200A1 (es) |
| EP (1) | EP3464292B8 (es) |
| JP (3) | JP6771246B2 (es) |
| KR (2) | KR20190026731A (es) |
| CN (1) | CN109563103B (es) |
| AR (1) | AR108772A1 (es) |
| AU (2) | AU2017278102B2 (es) |
| CA (1) | CA3026024A1 (es) |
| CL (1) | CL2018003451A1 (es) |
| CO (1) | CO2019000041A2 (es) |
| CR (1) | CR20180595A (es) |
| DK (1) | DK3464292T3 (es) |
| EA (1) | EA201892817A1 (es) |
| EC (1) | ECSP19001018A (es) |
| ES (1) | ES2929737T3 (es) |
| IL (2) | IL289378B (es) |
| MA (2) | MA44037B1 (es) |
| MX (2) | MX387995B (es) |
| MY (1) | MY195982A (es) |
| NI (1) | NI201800130A (es) |
| NZ (1) | NZ749202A (es) |
| PE (1) | PE20190445A1 (es) |
| PH (1) | PH12018502550B1 (es) |
| PT (1) | PT3464292T (es) |
| SG (1) | SG11201810788QA (es) |
| TN (1) | TN2018000391A1 (es) |
| TW (2) | TWI752963B (es) |
| UA (1) | UA125120C2 (es) |
| WO (1) | WO2017214002A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA44037B1 (fr) | 2016-06-06 | 2020-03-31 | Arena Pharm Inc | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci |
| EA201992215A1 (ru) | 2017-03-20 | 2020-02-06 | Форма Терапьютикс, Инк. | Пирролопирроловые композиции в качестве активаторов пируваткиназы (pkr) |
| TWI822713B (zh) * | 2017-12-06 | 2023-11-21 | 美商艾尼納製藥公司 | 適用於治療或預防與其相關之病症之β－３腎上腺素受體的調節劑 |
| US10675274B2 (en) | 2018-09-19 | 2020-06-09 | Forma Therapeutics, Inc. | Activating pyruvate kinase R |
| EP3852791B1 (en) | 2018-09-19 | 2024-07-03 | Novo Nordisk Health Care AG | Activating pyruvate kinase r |
| WO2021055807A1 (en) | 2019-09-19 | 2021-03-25 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| EP4384169A1 (en) * | 2021-08-09 | 2024-06-19 | Arena Pharmaceuticals, Inc. | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure |
| CA3230339A1 (en) * | 2021-08-26 | 2023-03-02 | Arena Pharmaceuticals, Inc. | Modulators of the beta-3 adrenergic receptor for the treatment or prevention of renal cystic disease and cardiorenal syndrome |
| EP4413005A1 (en) * | 2021-10-06 | 2024-08-14 | Arena Pharmaceuticals, Inc. | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto |
| US20250152574A1 (en) * | 2022-02-14 | 2025-05-15 | Biogen Ma Inc. | Emopamil-binding protein inhibitors and uses thereof |
| CN114539103B (zh) * | 2022-03-21 | 2023-04-07 | 佳木斯黑龙农药有限公司 | 2-二氟乙氧基-6-三氟甲基苯磺酰氯的合成方法 |
| CN116178220A (zh) * | 2022-12-13 | 2023-05-30 | 爱斯特（成都）生物制药股份有限公司 | 一种制备(2s)-2-[[3-(甲基磺酰基l)苯氧基]甲基]环氧乙烷的方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3028340C2 (de) * | 1980-07-25 | 1987-02-05 | Dr. Willmar Schwabe GmbH & Co, 7500 Karlsruhe | Amino-desoxy-1.4;3.6-dianhydro-hexit-nitrate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen |
| US5254595A (en) | 1988-12-23 | 1993-10-19 | Elf Sanofi | Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them |
| FR2751646B1 (fr) | 1996-07-23 | 1999-01-22 | Sanofi Sa | Phenoxypropanolamine a action antagoniste beta3-adrenergique |
| AU7738298A (en) | 1996-12-19 | 1998-07-15 | Agrevo Uk Limited | Chromones useful as fungicides |
| FR2780057B1 (fr) * | 1998-06-18 | 2002-09-13 | Sanofi Sa | Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant |
| AU2525801A (en) * | 1999-12-17 | 2001-06-25 | Sanofi-Synthelabo | Phenoxypropanolamines, method for producing them and pharmaceutical compositionscontaining them |
| DE20204129U1 (de) | 2002-03-15 | 2002-07-25 | Wella Ag, 64295 Darmstadt | Mittel zur Färbung von Keratinfasern mit Chinolinium-Farbstoffen |
| WO2005092860A1 (en) * | 2004-03-23 | 2005-10-06 | Pfizer Limited | Compounds for the treatment of diseases |
| WO2006060122A2 (en) * | 2004-11-30 | 2006-06-08 | Artesian Therapeutics, Inc. | Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase |
| US8697674B2 (en) | 2004-12-29 | 2014-04-15 | Naturon, Inc. | Xanthurenic acid derivative pharmaceutical compositions and methods related thereto |
| WO2008094507A2 (en) | 2007-01-26 | 2008-08-07 | Cellicon Biotechnologies, Inc. | Novel fusion compounds |
| US8039505B2 (en) | 2007-04-11 | 2011-10-18 | University Of Utah Research Foundation | Compounds for modulating T-cells |
| WO2009059225A2 (en) | 2007-11-02 | 2009-05-07 | Pain Therapeutics, Inc. | Analgesia with minimal tolerance and dependence by a mu opioid receptor agonist that also binds filamin a |
| US20100279997A1 (en) | 2009-05-04 | 2010-11-04 | Lindsay Burns Barbier | Analgesic that binds filamin a |
| WO2010051497A1 (en) | 2008-10-31 | 2010-05-06 | Pain Therapeutics, Inc. | Filamin a binding anti-inflammatory and analgesic |
| AU2009308769B2 (en) | 2008-10-31 | 2015-03-12 | Pain Therapeutics, Inc. | Filamin A-binding anti-inflammatory analgesic |
| WO2010058318A1 (en) * | 2008-11-21 | 2010-05-27 | Pfizer Inc. | 1-oxa-8-azaspiro [4, 5 ] decane- 8 -carboxamide compounds as faah inhibitors |
| US8785634B2 (en) * | 2010-04-26 | 2014-07-22 | Merck Sharp & Dohme Corp | Spiropiperidine prolylcarboxypeptidase inhibitors |
| JP5795799B2 (ja) * | 2010-07-23 | 2015-10-14 | メルク・シャープ・エンド・ドーム・コーポレイション | 新規なピロリジン由来ベータ３アドレナリン作動性受容体アゴニスト |
| JP2012092038A (ja) | 2010-10-26 | 2012-05-17 | F Hoffmann La Roche Ag | 糖尿病、糖尿病関連疾患又は糖尿病性合併症の予防又は治療剤 |
| JP6417324B2 (ja) | 2012-07-13 | 2018-11-07 | ペイン セラピューティクス インコーポレイテッド | τリン酸化を阻害する方法 |
| WO2014012054A1 (en) | 2012-07-13 | 2014-01-16 | Pain Therapeutics, Inc. | Alzheimer's disease assay in a living patent |
| GB201405359D0 (en) | 2014-03-25 | 2014-05-07 | Univ Liverpool | Synthetic process |
| MA44037B1 (fr) | 2016-06-06 | 2020-03-31 | Arena Pharm Inc | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci |
| TWI822713B (zh) * | 2017-12-06 | 2023-11-21 | 美商艾尼納製藥公司 | 適用於治療或預防與其相關之病症之β－３腎上腺素受體的調節劑 |
-
2017
- 2017-06-04 MA MA44037A patent/MA44037B1/fr unknown
- 2017-06-05 UA UAA201900139A patent/UA125120C2/uk unknown
- 2017-06-05 TN TNP/2018/000391A patent/TN2018000391A1/en unknown
- 2017-06-05 CA CA3026024A patent/CA3026024A1/en active Pending
- 2017-06-05 AU AU2017278102A patent/AU2017278102B2/en active Active
- 2017-06-05 MA MA045150A patent/MA45150A/fr unknown
- 2017-06-05 MY MYPI2018002257A patent/MY195982A/en unknown
- 2017-06-05 KR KR1020197000005A patent/KR20190026731A/ko not_active Withdrawn
- 2017-06-05 NZ NZ749202A patent/NZ749202A/en not_active IP Right Cessation
- 2017-06-05 ES ES17730638T patent/ES2929737T3/es active Active
- 2017-06-05 PH PH1/2018/502550A patent/PH12018502550B1/en unknown
- 2017-06-05 MX MX2018015124A patent/MX387995B/es unknown
- 2017-06-05 CN CN201780047870.6A patent/CN109563103B/zh active Active
- 2017-06-05 US US16/307,830 patent/US20190284200A1/en not_active Abandoned
- 2017-06-05 WO PCT/US2017/035867 patent/WO2017214002A1/en not_active Ceased
- 2017-06-05 DK DK17730638.8T patent/DK3464292T3/da active
- 2017-06-05 PE PE2018003180A patent/PE20190445A1/es unknown
- 2017-06-05 SG SG11201810788QA patent/SG11201810788QA/en unknown
- 2017-06-05 CR CR20180595A patent/CR20180595A/es unknown
- 2017-06-05 KR KR1020227004041A patent/KR102408272B1/ko active Active
- 2017-06-05 JP JP2019516084A patent/JP6771246B2/ja active Active
- 2017-06-05 EP EP17730638.8A patent/EP3464292B8/en active Active
- 2017-06-05 EA EA201892817A patent/EA201892817A1/ru unknown
- 2017-06-05 IL IL289378A patent/IL289378B/en unknown
- 2017-06-05 PT PT177306388T patent/PT3464292T/pt unknown
- 2017-06-06 TW TW106118610A patent/TWI752963B/zh active
- 2017-06-06 TW TW110147004A patent/TWI784840B/zh active
- 2017-06-06 AR ARP170101546A patent/AR108772A1/es active IP Right Grant
-
2018
- 2018-11-20 IL IL263148A patent/IL263148B/en unknown
- 2018-12-03 CL CL2018003451A patent/CL2018003451A1/es unknown
- 2018-12-05 NI NI201800130A patent/NI201800130A/es unknown
- 2018-12-05 MX MX2021014043A patent/MX2021014043A/es unknown
-
2019
- 2019-01-04 CO CONC2019/0000041A patent/CO2019000041A2/es unknown
- 2019-01-07 EC ECSENADI20191018A patent/ECSP19001018A/es unknown
- 2019-06-04 US US16/431,209 patent/US10479797B2/en active Active
- 2019-09-06 US US16/563,353 patent/US10662200B2/en active Active
-
2020
- 2020-05-12 US US16/872,812 patent/US10927123B2/en active Active
- 2020-09-18 JP JP2020157196A patent/JP7083087B2/ja active Active
- 2020-12-14 US US17/120,759 patent/US11560386B2/en active Active
-
2021
- 2021-07-20 AU AU2021206809A patent/AU2021206809B2/en active Active
-
2022
- 2022-04-21 JP JP2022069821A patent/JP7449329B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20190445A1 (es) | Moduladores del receptor beta-3 adrenergico de utilidad para el tratamiento o la prevencion de trastornos relacionados con ellos | |
| CO2020015153A2 (es) | Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos | |
| CL2018001414A1 (es) | Anticuerpos contra cd73 y sus usos (divisional solicitud 201701296) | |
| CO2017012545A2 (es) | Sulfonas tricíclicas como moduladores del receptor huérfano relacionado con retinoide gamma (rorγ) | |
| MX382230B (es) | Composiciones y metodos para modular la expresion de similar a la angiopoyetina tipo 3. | |
| MX2018003833A (es) | Composiciones y metodos para inhibir la expresion genica de lpa. | |
| DOP2022000042A (es) | Compuestos inhibidores de rip1 y métodos para prepararlos y usarlos | |
| BR112018015273A2 (pt) | derivados de benzimidazol como moduladores de ror-gama | |
| AR114156A1 (es) | MODULADORES DEL RECEPTOR ADRENÉRGICO b-3 ÚTILES PARA EL TRATAMIENTO O LA PREVENCIÓN DE TRASTORNOS RELACIONADOS CON ESTE | |
| EP2498797A4 (en) | TREATMENT OF CARDIOPATHY | |
| WO2016022536A3 (en) | Inhibitors of myh7b and uses thereof | |
| BR112018071602A2 (pt) | compostos de imidazopiridina substituídos como inibidores da indolamina 2,3-dioxigenase e/ou triptofano-2,3-dioxigenase | |
| CO2018002045A2 (es) | Derivados de 2-amino-nicotinamida y 3-amino-pirazin-2-carboxamida | |
| MX2017016347A (es) | Terapia de combinacion de activador de miosina cardiaca e inhibidor de corriente if del nodo sinusal. | |
| AR100715A1 (es) | Derivados de alquilo de compuestos 1-oxa-4,9-diazaespiro undeceno que tienen actividad multimodal contra el dolor | |
| EA201791021A1 (ru) | 1-[2-(АМИНОМЕТИЛ)БЕНЗИЛ]-2-ТИОКСО-1,2,3,5-ТЕТРАГИДРО-4H-ПИРРОЛО[3,2-d]ПИРИМИДИН-4-ОНЫ КАК ИНГИБИТОРЫ МИЕЛОПЕРОКСИДАЗЫ | |
| UY36663A (es) | Anticuerpos anti-ap2 y agentes de unión al antígeno para tratar trastornos metabólicos | |
| EA201892514A1 (ru) | Промежуточные соединения для синтеза производных желчных кислот, в частности обетихолевой кислоты | |
| MX2021003904A (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor apj. | |
| WO2015074010A8 (en) | Compositions and methods for cardiac regeneration | |
| AR094018A1 (es) | Inhibidores de corrientes funny (if) para utilizar en un metodo de tratamiento y/o prevencion de la enfermedad cardiaca en caninos | |
| MD4763B1 (ro) | Compoziţie farmaceutică | |
| JOP20180111B1 (ar) | منظمات مستقبل أدريناليني بيتا-3 مفيدة لمعالجة او الوقاية من اضطرابات مرتبطة بها | |
| CL2009001497A1 (es) | Compuestos derivados de 2-(3-piridil)-indol sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de trastornos mediados por aldosterona sintetasa, tales como insuficiencia cardiaca, arritmia, fibrosis del miocardio, cardiomiopatia hipertrofica, entre otras. | |
| AR111816A1 (es) | Composiciones y métodos para reducir los triglicéridos en un sujeto que tiene función renal reducida |